Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Chemical Synapses01:26

Chemical Synapses

12.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.2K
Chemical Synapses01:26

Chemical Synapses

6.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
6.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

5.5K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue Donors.

JAMA neurology·2026
Same author

Critical Review of Cataractogenesis and Lens Contouring in Radiation Oncology.

Advances in radiation oncology·2026
Same author

Amyotrophic Lateral Sclerosis Recovery: A New Model System of Care Integrating Neuromuscular Rehabilitation With Clinical Stabilization in ALS.

Muscle & nerve·2026
Same author

Cerebroretinal Microangiopathy with Calcifications and Cysts (CRMCC): A 5-Year Diagnostic Challenge.

Diagnostics (Basel, Switzerland)·2026
Same author

Should Patients With Ocular Myasthenia Gravis Be Started on Immunosuppression to Prevent Generalization?

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2026
Same author

Between a Chiasm and a Hard Place.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2026

Related Experiment Video

Updated: Mar 10, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Ocular Neuromyotonia Associated with Chronic Inflammatory Demyelinating Polyneuropathy.

Nathan H Kung1, Robert C Bucelli1, Collin M McClelland2

  • 1Department of Neurology, Washington University in St. Louis , St. Louis, Missouri, USA.

Neuro-Ophthalmology (Aeolus Press)
|December 9, 2016
PubMed
Summary

Ocular neuromyotonia, a disorder causing double vision, was linked to a demyelinating neuropathy. Treatment with intravenous immunoglobulin (IVIg) resolved the condition, suggesting a connection between demyelination and this rare eye movement disorder.

Keywords:
Chronic inflammatory demyelinating polyneuropathydiplopiaocular motilityocular neuromyotonia

More Related Videos

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.2K
Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury
04:44

Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury

Published on: November 1, 2024

968

Related Experiment Videos

Last Updated: Mar 10, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.2K
Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury
04:44

Author Spotlight: Regenerative Roles of Muscle Proteins at Neuromuscular Junction Post-Nerve Injury

Published on: November 1, 2024

968

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Neurology

Background:

  • Ocular neuromyotonia (ONM) is a rare neuro-ophthalmic disorder causing intermittent double vision due to abnormal ocular motor nerve excitation.
  • The underlying mechanisms of ONM, particularly its association with systemic conditions, remain incompletely understood.

Observation:

  • A patient presented with ocular neuromyotonia (ONM) that developed concurrently with subacute demyelinating polyneuropathy, specifically chronic inflammatory demyelinating polyneuropathy (CIDP).

Findings:

  • The patient's ONM symptoms resolved after receiving intravenous immunoglobulin (IVIg) therapy for the underlying CIDP.
  • This case suggests a potential role for demyelination and ephaptic neurotransmission in the pathogenesis of ONM.

Implications:

  • This case provides novel evidence linking ONM to a systemic neurological condition (CIDP).
  • The resolution of ONM following IVIg treatment highlights the importance of addressing underlying demyelinating processes.
  • Further research into demyelination and ephaptic transmission may elucidate ONM's pathophysiology and guide therapeutic strategies.